INS and type 2 diabetes mellitus: Even if the effect of empagliflozin has been widely accepted in T2DM patients with CV risk, in a recent study conducted by Pérez-Belmonte et al. [30] regarding the resumption of empagliflozin in T2DM patients who were hospitalized for acute decompensated HF, no significant changes were found in their observational research, which included patients treated using in-hospital basal-bolus insulin vs. empagliflozin-basal insulin as their antihyperglycemic agents.